Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03417102 · ClinicalTrials.gov registry record · Phase 3
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT03417102 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 60 participants.
The verdict
NCT03417102, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication. In addition, the study assessed safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).
Interventions
- DRUG fitusiran
- DRUG Bypassing agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2021-06-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03417102
The ClinicalTrials.gov registry entry for NCT03417102 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fitusiran is the first listed.
NCT03417102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03417102 about?
NCT03417102 is a clinical study titled "A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors". The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication. In addition, the study assessed safety, quality of life, pha...
What is the current status of trial NCT03417102?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2018-02-14. Estimated completion is 2021-06-23.
What interventions are being tested in trial NCT03417102?
The interventions under investigation include: fitusiran (DRUG), Bypassing agents (DRUG).
Who is sponsoring clinical trial NCT03417102?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.